Portable, low-cost hardware for decentralized COVID-19 diagnostics for Canada, Colombia, and Ecuador
- Funded by International Development Research Centre (IDRC)
- Total publications:1 publications
Grant number: 109547
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$323,043.98Funder
International Development Research Centre (IDRC)Principal Investigator
Keith PardeeResearch Location
CanadaLead Research Institution
The Governing Council of the University of TorontoResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
Innovation
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Health PersonnelHospital personnel
Abstract
The unfolding COVID-19 pandemic highlights the critical need for a diverse diagnostics strategy. Reliance on a single, highly centralized diagnostic technology, such as polymerase chain reaction (PCR), has led to supply chain disruption and bottlenecks in testing access. As attention is turning to the tools needed to relaunch economies, two capabilities have been identified as key: decentralized diagnostic testing for COVID-19 and serological testing to screen population antibody levels. This project aims to develop, validate, and implement the molecular tools and hardware required to support the decentralized, high-capacity diagnostic and serological testing to respond to the COVID-19 pandemic in Canada, Colombia, and Ecuador. The team proposes adapting a previously designed portable plate reader to deploy two key diagnostic modalities: a rapid (15 minute) molecular COVID-19 virologic test and serological testing of antibodies. Implementation and testing of this decentralized diagnostic capacity will be performed at small businesses in Canada, and with hospital workers and remote populations in Colombia and Ecuador. Together these tests will prevent a resurgence of infections as communities begin to reduce lockdown restrictions. It will also determine the prevalence of antibody levels in the population, which may help to promote strategic use of future vaccine stocks. The project was selected for funding through the COVID-19 May 2020 Rapid Research Funding Opportunity, coordinated by the Canadian Institutes of Health Research in partnership with IDRC and several other health research funding agencies across Canada.
Publicationslinked via Europe PMC
Last Updated:an hour ago
View all publications at Europe PMC